The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination
Abstract
Tumor vaccines for cancer prevention and treatment have attracted tremendous interests in the area of cancer immunotherapy in recent years. In this work, we present a strategy to construct cancer vaccines by encapsulating immune-adjuvant nanoparticles with cancer cell membranes modified by mannose. Poly(d,l-lactide- co-glycolide) nanoparticles are first loaded with toll-like receptor 7 agonist, imiquimod (R837). Those adjuvant nanoparticles (NP-R) are then coated with cancer cell membranes (NP-R@M), whose surface proteins could act as tumor-specific antigens. With further modification with mannose moiety (NP-R@M-M), the obtained nanovaccine shows enhanced uptake by antigen presenting cells such as dendritic cells, which would then be stimulated to the maturation status to trigger antitumor immune responses. With great efficacy to delay tumor development as a prevention vaccine, vaccination with such NP-R@M-M in combination with checkpoint-blockade therapy further demonstrates outstanding therapeutic efficacy to treat established tumors. Therefore, our work presents an innovative way to fabricate cancer nanovaccines, which in principle may be applied for a wide range of tumor types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Lutz, M. B., Kukutsch, N., Ogilvie, A. L. J., Rößner, S., Koch, F., Romani, N., & Schuler, G. (1999) · Journal of Immunological Methods · doi:10.1016/s0022-1759(98)00204-x · Cited by 2,966
Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform
Hu, C.-M. J., Zhang, L., Aryal, S., Cheung, C., Fang, R. H., & Zhang, L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106634108 · Cited by 2,433
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Chen, Q., Xu, L., Liang, C., Wang, C., Peng, R., & Liu, Z. (2016) · Nature Communications · doi:10.1038/ncomms13193 · Cited by 1,596
Self-citationBetts, M. R., Brenchley, J. M., Price, D. A., De Rosa, S. C., Douek, D. C., Roederer, M., & Koup, R. A. (2003) · Journal of Immunological Methods · doi:10.1016/s0022-1759(03)00265-5 · Cited by 1,587
Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery
Fang, R. H., Hu, C.-M. J., Luk, B. T., Gao, W., Copp, J. A., Tai, Y., O’Connor, D. E., & Zhang, L. (2014) · Nano Letters · doi:10.1021/nl500618u · Cited by 1,501
Cancer immunotherapy: harnessing the immune system to battle cancer
Yang, Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83871 · Cited by 1,359
Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302
Self-citationCombination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Nanoparticles target distinct dendritic cell populations according to their size
Manolova, V., Flace, A., Bauer, M., Schwarz, K., Saudan, P., & Bachmann, M. F. (2008) · European Journal of Immunology · doi:10.1002/eji.200737984 · Cited by 1,289
Antitumor and antimetastatic activity of interleukin 12 against murine tumors.
Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., & Gately, M. K. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.4.1223 · Cited by 1,197
Cellular Uptake, Intracellular Trafficking, and Cytotoxicity of Nanomaterials
Zhao, F., Zhao, Y., Liu, Y., Chang, X., Chen, C., & Zhao, Y. (2011) · Small · doi:10.1002/smll.201100001 · Cited by 1,175
Self-citationParodi, A., Quattrocchi, N., van de Ven, A. L., Chiappini, C., Evangelopoulos, M., Martinez, J. O., Brown, B. S., Khaled, S. Z., Yazdi, I. K., Enzo, M. V., et al. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2012.212 · Cited by 1,168
Dendritic-cell trafficking to lymph nodes through lymphatic vessels
Randolph, G. J., Angeli, V., & Swartz, M. A. (2005) · Nature Reviews Immunology · doi:10.1038/nri1670 · Cited by 1,111
Designer vaccine nanodiscs for personalized cancer immunotherapy
Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A., & Moon, J. J. (2017) · Nature Materials · doi:10.1038/nmat4822 · Cited by 1,056
Dendritic Cell Subsets and Lineages, and Their Functions in Innate and Adaptive Immunity
Liu, Y.-J. (2001) · Cell · doi:10.1016/s0092-8674(01)00456-1 · Cited by 1,004
Programming the magnitude and persistence of antibody responses with innate immunity
Kasturi, S. P., Skountzou, I., Albrecht, R. A., Koutsonanos, D., Hua, T., Nakaya, H. I., Ravindran, R., Stewart, S., Alam, M., Kwissa, M., et al. (2011) · Nature · doi:10.1038/nature09737 · Cited by 975
Gattinoni, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24480 · Cited by 958
Targeted Gold Nanoparticles Enable Molecular CT Imaging of Cancer
Popovtzer, R., Agrawal, A., Kotov, N. A., Popovtzer, A., Balter, J., Carey, T. E., & Kopelman, R. (2008) · Nano Letters · doi:10.1021/nl8029114 · Cited by 801
Cancer vaccines: between the idea and the reality
Finn, O. J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1150 · Cited by 636
In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy
Wang, C., Sun, W., Ye, Y., Hu, Q., Bomba, H. N., & Gu, Z. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0011 · Cited by 526
Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity
Kroll, A. V., Fang, R. H., Jiang, Y., Zhou, J., Wei, X., Yu, C. L., Gao, J., Luk, B. T., Dehaini, D., Gao, W., et al. (2017) · Advanced Materials · doi:10.1002/adma.201703969 · Cited by 501
Immunotherapy of cancer in 2012
Kirkwood, J. M., Butterfield, L. H., Tarhini, A. A., Zarour, H., Kalinski, P., & Ferrone, S. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20132 · Cited by 436
Guo, Y., Wang, D., Song, Q., Wu, T., Zhuang, X., Bao, Y., Kong, M., Qi, Y., Tan, S., & Zhang, Z. (2015) · ACS Nano · doi:10.1021/acsnano.5b01042 · Cited by 413
A melanin-mediated cancer immunotherapy patch
Ye, Y., Wang, C., Zhang, X., Hu, Q., Zhang, Y., Liu, Q., Wen, D., Milligan, J., Bellotti, A., Huang, L., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aan5692 · Cited by 381
Iclozan, C., Antonia, S., Chiappori, A., Chen, D.-T., & Gabrilovich, D. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1396-8 · Cited by 317
Dendritic cells: versatile controllers of the immune system
Steinman, R. M. (2007) · Nature Medicine · doi:10.1038/nm1643 · Cited by 316
Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook
Wang, C., Ye, Y., Hu, Q., Bellotti, A., & Gu, Z. (2017) · Advanced Materials · doi:10.1002/adma.201606036 · Cited by 286
Reconstructed Stem Cell Nanoghosts: A Natural Tumor Targeting Platform
Toledano Furman, N. E., Lupu-Haber, Y., Bronshtein, T., Kaneti, L., Letko, N., Weinstein, E., Baruch, L., & Machluf, M. (2013) · Nano Letters · doi:10.1021/nl401376w · Cited by 273
DEMONSTRATION OF THE OUTER SURFACE OF FREEZE-ETCHED RED BLOOD CELL MEMBRANES
Tillack, T. W., & Marchesi, V. T. (1970) · The Journal of Cell Biology · doi:10.1083/jcb.45.3.649 · Cited by 252
Xiang, J., Xu, L., Gong, H., Zhu, W., Wang, C., Xu, J., Feng, L., Cheng, L., Peng, R., & Liu, Z. (2015) · ACS Nano · doi:10.1021/acsnano.5b02014 · Cited by 230
Self-citationZhang, Z., Tongchusak, S., Mizukami, Y., Kang, Y. J., Ioji, T., Touma, M., Reinhold, B., Keskin, D. B., Reinherz, E. L., & Sasada, T. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.01.067 · Cited by 228
Tumor Promotion by Intratumoral Plasmacytoid Dendritic Cells Is Reversed by TLR7 Ligand Treatment
Le Mercier, I., Poujol, D., Sanlaville, A., Sisirak, V., Gobert, M., Durand, I., Dubois, B., Treilleux, I., Marvel, J., Vlach, J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3058 · Cited by 195
IL-12p70–producing patient DC vaccine elicits Tc1-polarized immunity
Carreno, B. M., Becker-Hapak, M., Huang, A., Chan, M., Alyasiry, A., Lie, W.-R., Aft, R. L., Cornelius, L. A., Trinkaus, K. M., & Linette, G. P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68395 · Cited by 164
Lodge, P. A., Jones, L. A., Bader, R. A., Murphy, G. P., & Salgaller, M. L. (2000) · PubMed · Cited by 160
Li, P., Luo, Z., Liu, P., Gao, N., Zhang, Y., Pan, H., Liu, L., Wang, C., Cai, L., & Ma, Y. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.03.025 · Cited by 158
A Facile Approach to Functionalize Cell Membrane-Coated Nanoparticles
Zhou, H., Fan, Z., Lemons, P. K., & Cheng, H. (2016) · Theranostics · doi:10.7150/thno.15095 · Cited by 152
Carrillo‐Conde, B., Song, E.-H., Chavez-Santoscoy, A. V., Phanse, Y., Ramer‐Tait, A. E., Pohl, N. L. B., Wannemuehler, M. J., Bellaire, B. H., & Narasimhan, B. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200213r · Cited by 147
Marrache, S., Tundup, S., Harn, D. A., & Dhar, S. (2013) · ACS Nano · doi:10.1021/nn403158n · Cited by 144
Xu, L., Liu, Y., Chen, Z., Li, W., Liu, Y., Wang, L., Ma, L., Shao, Y., Zhao, Y., & Chen, C. (2013) · Advanced Materials · doi:10.1002/adma.201300583 · Cited by 142
Self-citationPreparation of multifunctional nanoparticles and their assemblies
McCarthy, S. A., Davies, G., & Gun’ko, Y. K. (2012) · Nature Protocols · doi:10.1038/nprot.2012.082 · Cited by 121
Christensen, D., Henriksen‐Lacey, M., Kamath, A. T., Lindenstrøm, T., Korsholm, K. S., Christensen, J. P., Rochat, A., Lambert, P., Andersen, P. L., Siegrist, C., et al. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.016 · Cited by 113
Blonder, J., Chan, K. C., Issaq, H. J., & Veenstra, T. D. (2006) · Nature Protocols · doi:10.1038/nprot.2006.359 · Cited by 110
Cancer, Immune Function, and Physical Activity
Shephard, R. J., & Shek, P. N. (1995) · Canadian Journal of Applied Physiology · doi:10.1139/h95-001 · Cited by 107
Shevtsov, M. A., Nikolaev, B. P., Yakovleva, L. Y., Parr, M. A., Marchenko, Y., Eliseev, I. E., Yudenko, A., Добродумов, А. В., Злобина, О. В., Zhakhov, A. V., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.051 · Cited by 83
Structural elucidation of cell membrane-derived nanoparticles using molecular probes
Fan, Z., Zhou, H., Li, P. Y., Speer, J. E., & Cheng, H. (2014) · Journal of Materials Chemistry B · doi:10.1039/c4tb00980k · Cited by 63
Promising particle-based vaccines in cancer therapy
Xiang, S. D., Scalzo‐Inguanti, K., Minigo, G., Park, A. J., Hardy, C. L., & Plebanski, M. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.7.1103 · Cited by 61
Branca, M. A. (2016) · Nature Biotechnology · doi:10.1038/nbt.3690 · Cited by 43
Gong, H., Xiang, J., Xu, L., Song, X., Dong, Z., Peng, R., & Liu, Z. (2015) · Nanoscale · doi:10.1039/c5nr06081h · Cited by 27
Self-citationModeling flow cytometry data for cancer vaccine immune monitoring
Frelinger, J., Ottinger, J. S., Gouttefangeas, C., & Chan, C. C. W. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0883-4 · Cited by 26
Cited by
Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance
Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00193 · Cited by 1,451
Self-citationNanoparticles for Cancer Therapy: Current Progress and Challenges
Gavas, S., Quazi, S., & Karpiński, T. M. (2021) · Nanoscale Research Letters · doi:10.1186/s11671-021-03628-6 · Cited by 1,069
Platinum-based drugs for cancer therapy and anti-tumor strategies
Zhang, C., Xu, C., Gao, X., & Yao, Q. (2022) · Theranostics · doi:10.7150/thno.69424 · Cited by 1,018
Targeting drugs to tumours using cell membrane-coated nanoparticles
Fang, R. H., Gao, W., & Zhang, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00699-x · Cited by 980
Xu, J., Lv, J., Zhuang, Q., Yang, Z., Cao, Z., Xu, L., Pei, P., Wang, C., Wu, H., Dong, Z., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-00781-4 · Cited by 561
Self-citation
Metadata
- Authors
- Yang, R., Xu, J., Xu, L., Sun, X., Chen, Q., Zhao, Y., Peng, R., & Liu, Z.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-05-17
- Volume
- 12
- Issue
- 6
- Pages
- 5121-5129
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2804447831
- Cited by
- 698
- References
- 53
- FWCI
- 23.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
